POSTER'20'
PAROTITIS'AS'AN'ADVERSE'EVENT'OF'CYTARABINE'
'
Maria!Eduarda!Couto,!Nelson!Domingues,!Isabel!Oliveira!and!José!Mariz,!!
!
OncoUhematology!Service,!Instituto!Português!de!Oncologia!do!Porto,!F.G.,!E.P.E.,!Porto,!Portugal!
!
Introduction:!Chemotherapy!causes!many!adverse!events,!according!to!the!combination!of!
agents!used.!The!aggressiveness!of!the!oncologic!disease!itself!is!also!a!relevant!risk!factor!
for!rare!adverse!events.!
Aim' and' Methods:!The! clinical! file! of! a! patient! diagnosed! and! treated! in! our! center! was!
reviewed,! in! order! to! characterize! the! disease! course! and! better! understand! the!
complications!underlying!her!treatment.!
Results:!A!39!yearJold!female!developed!left!hemiparesis!and!choreiform!movements,!being!
identified!a!central!nervous!system!diffuse!large!BJcell!nonJHodgkin!lymphoma!(DLBC!NHL).!
The!De! Angelis!protocol! was! completed! after! radiotherapy,! being! achieved! a! complete!
response.!
Along! her! chemotherapy! treatment! she! developed! 3! episodes! of! meningitis! and! epileptic!
crisis! caused! by! infection! in! the! Ommaya! catheter.! Afterwards! she! maintained!
anticonvulsive!therapy!for!partial!crisis.!After!the!first!dose!of!cytarabine!a!bilateral!oedema!
in!the!parotid!region!was!identified.!While!on!the!second!phase!of!high!dose!cytarabine,!the!
patient! developed! fever! and! the! bilateral! oedema! worsened! progressively,! with! erythema!
and!high!sensitivity!to!touch.!Intravenous!ceftriaxone!was!started!(1!administration,!with!no!
more! febrile! events),! followed! by! oral! amoxicillin! and! clavulanic! acid! for! 1! week.! After! 2!
weeks! the! patient! completely! recovered! in! the! ambulatory! settings.! Peripheral! blood!
cultures!were!negative.!
One! year! after! the! diagnosis! the! disease! relapsed! as! a! peripheral! DLBC! NHL,! stage! IV!
(pancreas,! myocardium,! supraJadrenals! and! uterus! involvement,! without! cerebral! lesion).!
She!did!2RJACVBP!(with!bad!tolerance)!and!2!RJCHOP,!followed!by!autologous!bone!marrow!
transplant!(after!the!conditioning!regiment!BEAM)!achieving!a!complete!response.!After!the!
transplant!she!developed!a!hemophagocytic!syndrome,!handled!with!corticosteroids.!There!
was!no!relapse!of!the!parotitis!in!this!second!line!treatment.!
Conclusion:!This! patient! had! several! complications! along! her! disease! course.! Parotitis! is! a!
rare!but!reported!adverse!event!with!cytarabine!that!did!not!influence!negatively!the!course!
of!this!disease!or!its!treatment.!
' '
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES